Healthcare giant Johnson & Johnson (JNJ) kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the
Johnson & Johnson Q1 earnings slide on flat revenue growth
Categories
Health Care
UnitedHealth Group’s stock gains after Q1 results beat estimates
UnitedHealth Group (NYSE:UNH) beat market estimates on both revenue and earnings for the first quarter of 2019, allowing the stock to gain
Aphria stock sinks on disappointing Q3 bottom-line
Shares of Canadian cannabis company Aphria Inc (NYSE:APHA) fell 8.9% during the pre-market hours on Monday after it reported a third-quarter adjusted
Earnings Preview: New deals and international expansion could boost Aphria’s Q3 results
Aphria Inc. (NYSE: APHA and TSX: APHA) is set to release its financial results for the fiscal third quarter and nine months
Earnings preview: Johnson & Johnson (JNJ) to stay buoyant in Q1 despite challenges
Johnson & Johnson (NYSE: JNJ), one of the first healthcare companies to publish quarterly results this season, will be reporting March-quarter results
Rite Aid posts narrower-than-expected Q4 loss
Drugstore chain Rite Aid Corporation (NYSE: RAD) reported a narrower loss from continuing operations in the fourth quarter as it delivered the
Marijuana vs US: Will Aurora Cannabis survive in the banned market?
In the US, marijuana has been slowly turning to be legal in certain states but it still remained banned at the federal
Novartis (NVS) stock falls after Alcon spin-off; predicts stable growth ahead
Nearly a year after laying out its transformation strategy, with focus on demerging underperforming business units, Novartis (NYSE: NVS) Tuesday said it
Viveve Medical stock plunges to 9-year low
Viveve Medical Inc. (NASDAQ: VIVE) stock plunged to a 9-year low of $0.58 on Monday. Investors were concerned about the future of
Aurora Cannabis on a high after securing production approval in Germany
Aurora Cannabis Inc. (NYSE: ACB) got a shot in the arm this week after the German authorities granted it approval to cultivate
Evoke Pharma stock tumbles to 5-year low
Evoke Pharma Inc. (NASDAQ: EVOK) stock tumbled to over 5-year low of $0.76 on Thursday. Investors remained concerned on the future of
InspireMD, ReWalk Robotics decline on stock offering
Two Israeli firms – InspireMD (NYSE: NSPR) and ReWalk Robotics (NASDAQ: RWLK) – saw their shares fall during the pre-market hours of
Walgreens Boots Alliance posts Q2 earnings, cuts 2019 outlook
Retailing giant Walgreens Boots Alliance (WBA) posted its second-quarter 2019 earnings before the bell on Tuesday, April 2. For the quarter, sales inched
AngioDynamics misses Q3 earnings
AngioDynamics (NASDAQ: ANGO) posted third-quarter earnings on Tuesday before the regular trading hours. Net sales for the period increased 3% to $86.3 million,
Celgene stock jumps after advisory firm backs merger with Bristol-Myers Squibb
The planned acquisition of Celgene (CELG) by rival drugmaker Bristol-Myers Squibb (BMY) got a new lease of life this week after proxy
AstraZeneca drops 6% after announcing $6.9 billion cancer drug deal with Daiichi Sankyo
Shares of AstraZeneca Plc (NYSE: AZN) dropped about 6% on NYSE during the pre-market hours and continued to trade in the negative
Biocept narrows loss in Q4
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Advaxis shares plummet after reverse stock-split announcement
Nasdaq-listed late-stage biotech firm Advaxis, Inc. (NASDAQ:ADXS) focusses on discovery, development, and commercialization of immunotherapy products. The latest from this company is
Why Amarin stock is rallying today
Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American Diabetes Association
Arcadia Biosciences stock down despite solid Q4 results
Arcadia Biosciences (RKDA) stock decreased by nearly 2% in the extended hours of trading despite the fourth quarter results surpassed analysts’ estimates.
Earnings preview: What’s on the cards for Biocept in Q4
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.